Provinces/Municipalities. The virus has raised severe concerns due to its ability of binding to receptors in the upper respiratory tract 4 and the high death rate in human infections. Several published studies have presented preliminary analyses of the risk factors or predictors for fatal human infections with H7N9. [5] [6] [7] However, statistical analyses, especially multivariate analyses, were underpowered in most studies 
| METHODS

| Subjects
All laboratory-confirmed human infections with H7N9 are reported through a national system for reporting of notifiable infectious diseases. 8 Demographic, epidemiological and clinical information on patients infected with H7N9 was collected using standardized questionnaires by local CDC staff or trained clinical doctors in Jiangsu
Province and was reported through this system. All patients infected with H7N9 as of 1 June 2016 in Jiangsu Province were included in this analysis.
| Ethic statement
The National Health and Family Planning Commission ruled that the collection of data from cases of H7N9 was part of the public health investigation of an emerging outbreak, and thus, the investigation was exempt from institutional review board assessment. 8 Patients'
information was collected and reported to Jiangsu Provincial CDC and China CDC through a national system for reporting of notifiable infectious diseases. Jiangsu Provincial CDC is responsible for checking and monitoring the reported information and will take part in patients'
investigations if necessary. The data set was not anonymized in the reporting system but was anonymized before data analysis. Table S1 . Cases with missing data on variables being analysed were excluded. .005
| Statistical analysis
| RESULTS
Chronic metabolic disease, n (%) .850 5.00 (4.00-7.00) 5.00 (4.00-7.00)
.759
Time interval from onset of disease to laboratory confirmation, median (
12.00 (9.00-15.00) 10 .00 (8.00-12.00)
8.00 (7.00-12.00)
8.00 (7.00-11.50)
.007 10.00 (8.00-12.00)
10.00 (8.00-13.00)
.895
Time interval from onset of disease to antivirals administration, median (interquartile) 9.00 (5.00-14.00)
7.00 (6.00-9.00)
7.00 (6.00-9.00) 7.00 (5.00-8.50)
.567 7.00 (5.00-10.25)
.980
Time interval from onset of disease to glucocorticoids administration, median (interquartile) .028
Renal dysfunction, n (%) .012
Antibiotics, n (%) 
| DISCUSSION
H7N9 influenza virus continues to cause human infections and has resulted in four epidemic waves in Jiangsu Province, eastern China, up to June 2016. Both the proportion of overweight and of rural residents increased significantly across four waves in reported H7N9
patients. However, no significant difference in overweight between urban and rural H7N9 patients was observed (P=.937). Thus, the change in overweight might be attributed to the characteristics of subpopulations (cases were reported from different regions of Jiangsu Province across four waves) or to the overall rise of overweight rate in Jiangsu Province as a whole, rather than the involvement of more rural patients. According to the surveillance data of Jiangsu Provincial CDC, the overall obesity rate has increased from 9.5% to 14.6% from 2007 to 2013. It was reported that overweight could impair immunity against the influenza virus 9 and was associated with an increased risk of severe infection. 10 The increasing trend of overweight observed in the study has reminded public health experts of the importance of strengthening health education and of promoting precaution implementation in this high-risk population. Several major cities afflicted by H7N9 in Jiangsu Province, such as Nanjing, Suzhou, Wuxi and Zhenjiang, suspended live poultry markets (LPMs) in urban areas to alleviate human infections. 11 This may have boosted the live poultry trading in rural areas, leading to an increased number of rural H7N9 patients. A similar increasing trend was also observed in Zhejiang province, which was another hot spot of H7N9 epidemic in China. 12 The time interval from onset of disease to laboratory confirmation of H7N9 patients has been shortened from a median of 12 days to 8 days across four epidemic waves. This might be attributed to improved laboratory capacity of municipal Centers for Disease Control and Prevention (CDC), 13 avoiding repeated tests for confirmation by Provincial CDC. 3 In addition, increased awareness of clinical doctors and the public might also be involved. 13 A similar trend was also reported by Wu et al (2013) at the national level in China. 3 It seemed that patients' disease progress was fastest during the third epidemic wave, as the time interval from onset of disease to onset of ARDS and to respiratory failure, and the disease duration of fatal cases were all shortest during this wave. The observed highest prevalence of chronic cardiovascular disease (60%) in reported H7N9
cases of this wave might be responsible. Incidence of heart failure was highest in cases of this wave as well (50%, P=.023). This indicates a critical role of cardiovascular function in the prognosis of human infections with H7N9. 14, 15 A large majority of the cases were treated with neuraminidase inhibitors, and the implementation of a higher dose (150 mg) became the norm (from 15.8% to 90.5%). However, the higher dose was not found to be associated with a better prognosis in this study. We found in this study that clinical complications such as ARDS, heart failure and septic shock could pose an elevated risk of death from H7N9 infection. This finding is consistent with previous studies and case reports. [5] [6] [7] A longer disease duration was found to be associated with a reduced risk of death in our study. Previous studies also reported that the disease duration of fatal cases was shorter than that of patients who recovered. 22, 23 Infections with several avian influenza subtypes, such as H9N2, H7N7, H7N2, H7N3, H10N7 and H6N1, are commonly regarded as self-limiting diseases, 24 and essential supportive care has been proved to be effective for recovery. 25, 26 For H7N9, studies showed that viral load peaked within the first 10 days after symptom onset during the acute exudative phase, 27 and individuals'
anti-H7N9 antibodies could be detected from day 21, along with a significant decline of viral load. 28 This indicated that infection with H7N9
can also be considered self-limiting, which highlighted the critical role of supportive health care in treatment. We suggest that a disease duration of 25.5 days might serve as the time indicator for patients' survival.
Interestingly, administration of glucocorticoids was associated with a significantly elevated risk of death, while its clinical implementation jumped from a proportion of 61.5% to 100% across the observed four epidemic waves in this study. Glucocorticoid is mainly used as an anti-inflammatory agent and is also an alternative for the treatment of septic shock. [29] [30] [31] The administration of glucocorticoids thus reflects disease severity to some extent. However, as observed in this study, glucocorticoids have been used more and more comprehensively for treating H7N9 patient, not only restricted to these with special need. Treating influenza with glucocorticoids remains controversial. A number of studies have reported that use of glucocorticoids increased the death risk from H1N1 [32] [33] [34] [35] and from H5N1. 36 Slower viral clearance of influenza A (H3N2) virus was observed in patients treated with systemic glucocorticoid. 37 Furthermore, a systematic review and meta-analysis using data from 19 studies of glucocorticoid treatment and human infection of influenza virus have concluded that glucocorticoids were related with mortality, nosocomial infection, longer mechanical ventilation and longer ICU stay. 38 As a result, a much more rational use of glucocorticoids based on sturdy scientific evidences is urgently needed, 39 for instance, assessing patients' disease progression with objective medical indicators along with the types, doses and administrative routes of glucocorticoids.
In conclusion, the differences in epidemiological and clinical characteristics across four observed epidemic waves of H7N9 in Jiangsu of China were reported in this study and predictors for fatal infection were investigated using multivariate analyses based on a relatively large sample size. These results help us better understand the evolution of H7N9 and help clinicians prejudge the prognosis of H7N9
patients. Suggestions for appropriate medication treatment such as neuraminidase inhibitors doses and glucocorticoids administration were also provided.
